A detailed history of Quadrant Capital Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,481 shares of VRTX stock, worth $1.25 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,481
Previous 2,346 5.75%
Holding current value
$1.25 Million
Previous $980,000 18.57%
% of portfolio
0.09%
Previous 0.08%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $53,029 - $65,546
135 Added 5.75%
2,481 $1.16 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $11,007 - $12,044
27 Added 1.16%
2,346 $980,000
Q4 2023

Feb 08, 2024

BUY
$343.0 - $410.68 $24,696 - $29,568
72 Added 3.2%
2,319 $943,000
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $4,734 - $5,074
-14 Reduced 0.62%
2,247 $781,000
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $25,153 - $28,152
-80 Reduced 3.42%
2,261 $795,000
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $95,165 - $108,561
336 Added 16.76%
2,341 $737,000
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $2,000 - $2,250
-7 Reduced 0.35%
2,005 $579,000
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $44,086 - $49,190
161 Added 8.7%
2,012 $583,000
Q2 2022

Aug 09, 2022

BUY
$234.96 - $292.55 $77,301 - $96,248
329 Added 21.62%
1,851 $522,000
Q1 2022

May 06, 2022

BUY
$221.42 - $260.97 $22,142 - $26,097
100 Added 7.03%
1,522 $397,000
Q4 2021

Feb 01, 2022

BUY
$177.01 - $223.45 $40,712 - $51,393
230 Added 19.3%
1,422 $312,000
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $26,845 - $30,042
-148 Reduced 11.04%
1,192 $216,000
Q2 2021

Aug 09, 2021

SELL
$187.49 - $221.1 $20,998 - $24,763
-112 Reduced 7.71%
1,340 $270,000
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $6,624 - $7,721
32 Added 2.25%
1,452 $312,000
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $32,086 - $42,793
155 Added 12.25%
1,420 $336,000
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $4,090 - $4,849
16 Added 1.28%
1,265 $344,000
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $284,781 - $373,595
-1,263 Reduced 50.28%
1,249 $363,000
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $81,106 - $100,610
406 Added 19.28%
2,512 $594,000
Q4 2019

Feb 03, 2020

BUY
$166.71 - $223.91 $38,176 - $51,275
229 Added 12.2%
2,106 $435,000
Q3 2019

Oct 24, 2019

BUY
$166.23 - $187.09 $10,804 - $12,160
65 Added 3.59%
1,877 $305,000
Q2 2019

Jul 24, 2019

BUY
$164.61 - $190.37 $43,786 - $50,638
266 Added 17.21%
1,812 $319,000
Q1 2019

Apr 29, 2019

BUY
$163.73 - $194.7 $113,464 - $134,927
693 Added 81.24%
1,546 $270,000
Q4 2018

Jan 17, 2019

BUY
$151.91 - $192.21 $25,672 - $32,483
169 Added 24.71%
853 $125,000
Q3 2018

Oct 29, 2018

BUY
$167.73 - $192.74 $5,199 - $5,974
31 Added 4.75%
684 $122,000
Q2 2018

Aug 09, 2018

SELL
$145.72 - $169.96 $6,994 - $8,158
-48 Reduced 6.85%
653 $99,000
Q1 2018

May 10, 2018

BUY
$151.6 - $177.13 $11,218 - $13,107
74 Added 11.8%
701 $100,000
Q4 2017

Jan 31, 2018

BUY
$137.28 - $155.55 $411 - $466
3 Added 0.48%
627 $85,000
Q3 2017

Oct 13, 2017

BUY
$148.13 - $162.24 $5,480 - $6,002
37 Added 6.3%
624 $87,000
Q2 2017

Aug 15, 2017

BUY
N/A
587
587 $69,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.